The evolving role of dendritic cells in cancer therapy

Bibliography

• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989;54(Pt 1):1-13
   PubMedGoogle Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392(6673):245-52
   PubMed Web of Science ®Google Scholar
• Prestwich RJ, Errington F, Hatfield P, The immune system–is it relevant to cancer development, progression and treatment? Clin Oncol (R Coll Radiol) 2008;20(2):101-12
   PubMed Web of Science ®Google Scholar
• Tran KQ, Zhou J, Durflinger KH, Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 2008;31(8):742-51
   PubMed Web of Science ®Google Scholar
• Uyttenhove C, Pilotte L, Theate I, Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9(10):1269-74
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006;29(3):233-40
   PubMed Web of Science ®Google Scholar
• Lehmann C, Zeis M, Schmitz N, Uharek L. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood 2000;96(2):594-600
   PubMed Web of Science ®Google Scholar
• Real LM, Jimenez P, Kirkin A, Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol Immunother 2001;49(11):621-8
   PubMed Web of Science ®Google Scholar
• Shin MS, Kim HS, Lee SH, Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001;61(13):4942-6
   PubMed Web of Science ®Google Scholar
• Vicari AP, Caux C, Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 2002;12(1):33-42
   PubMed Web of Science ®Google Scholar
• Feijoo E, Alfaro C, Mazzolini G, Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer 2005;116(2):275-81
   PubMed Web of Science ®Google Scholar
• Tuyaerts S, Aerts JL, Corthals J, Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 2007;56(10):1513-37
   PubMed Web of Science ®Google Scholar
• Harzstark AL, Small EJ. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert Opin Biol Ther 2007;7(8):1275-80
   PubMed Web of Science ®Google Scholar
• Liau LM, Prins RM, Kiertscher SM, Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11(15):5515-25
   PubMed Web of Science ®Google Scholar
• Bohnenkamp HR, Noll T. Development of a standardized protocol for reproducible generation of matured monocyte-derived dendritic cells suitable for clinical application. Cytotechnology 2003;42(3):121-31
   PubMed Web of Science ®Google Scholar
• Dauer M, Obermaier B, Herten J, Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol 2003;170(8):4069-76
   PubMed Web of Science ®Google Scholar
• de Vries IJ, Lesterhuis WJ, Scharenborg NM, Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003;9(14):5091-100
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Steinman RM, Krasovsky J, Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193(2):233-8
   PubMed Web of Science ®Google Scholar
• Kalinski P, Hilkens CM, Snijders A, IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol 1997;159(1):28-35
   PubMed Web of Science ®Google Scholar
• Muthuswamy R, Urban J, Lee JJ, Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res 2008;68(14):5972-8
   PubMed Web of Science ®Google Scholar
• Morelli AE, Thomson AW. Dendritic cells under the spell of prostaglandins. Trends Immunol 2003;24(3):108-11
   PubMed Web of Science ®Google Scholar
• Sporri R, Reis e Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol 2005;6(2):163-70
   PubMed Web of Science ®Google Scholar
• Nakahara S, Tsunoda T, Baba T, Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 2003;63(14):4112-8
   PubMed Web of Science ®Google Scholar
• Boullart AC, Aarntzen EH, Verdijk P, Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother 2008;57(11):1589-97
   PubMed Web of Science ®Google Scholar
• Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006;6(6):476-83
   PubMed Web of Science ®Google Scholar
• Prestwich RJ, Errington F, Ilett EJ, Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 2008;14(22):7358-66
   PubMed Web of Science ®Google Scholar
• Jungbluth AA, Busam KJ, Kolb D, Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 2000;85(4):460-5
   PubMed Web of Science ®Google Scholar
• Jungbluth AA, Stockert E, Chen YT, Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer 2000;83(4):493-7
   PubMed Web of Science ®Google Scholar
• Gilboa E. DC-based cancer vaccines. J Clin Invest 2007;117(5):1195-203
   PubMed Web of Science ®Google Scholar
• Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005;54(3):187-207
   PubMed Web of Science ®Google Scholar
• Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008;8(5):351-60
   PubMed Web of Science ®Google Scholar
• Haenssle H, Buhl T, Riedl P, Intracellular delivery of antigenic peptides and poly(I:C) leads to full dendritic cell maturation, high IL-12 secretion and increased T cell stimulatory capacity. CIMT 6th Annual Meeting; 2008; Mainz
   Google Scholar
• Redman BG, Chang AE, Whitfield J, Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother 2008;31(6):591-8
   PubMed Web of Science ®Google Scholar
• Palucka AK, Ueno H, Connolly J, Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 2006;29(5):545-57
   PubMed Web of Science ®Google Scholar
• Marten A, Renoth S, Heinicke T, Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical Phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 2003;14(5):483-94
   PubMed Web of Science ®Google Scholar
• Prestwich RJ, Scott KJ, Brown J, The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma. BJU Int 2009;103(6):740-6
   PubMed Web of Science ®Google Scholar
• Hersey P, Halliday GM, Farrelly ML, Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. Cancer Immunol Immunother 2008;57(7):1039-51
   PubMed Web of Science ®Google Scholar
• Hersey P, Menzies SW, Halliday GM, Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 2004;53(2):125-34
   PubMed Web of Science ®Google Scholar
• Song W, Kong HL, Carpenter H, Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997;186(8):1247-56
   PubMed Web of Science ®Google Scholar
• Gong J, Chen L, Chen D, Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther 1997;4(10):1023-8
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Comin-Anduix B, Vujanovic L, Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 2008;31(3):294-309
   PubMed Web of Science ®Google Scholar
• Liao X, Li Y, Bonini C, Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther 2004;9(5):757-64
   PubMed Web of Science ®Google Scholar
• Fukushima S, Hirata S, Motomura Y, Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells. J Immunother 2009;32(3):219-31
   PubMed Web of Science ®Google Scholar
• Nair SK, Morse M, Boczkowski D, Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002;235(4):540-9
   PubMed Web of Science ®Google Scholar
• Kyte JA, Mu L, Aamdal S, Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006;13(10):905-18
   PubMed Web of Science ®Google Scholar
• Morse MA, Nair SK, Boczkowski D, The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer 2002;32(1):1-6
   PubMedGoogle Scholar
• Dörrie J, Schaft N, Wellner V, Many antigen presenting cells, or much antigen per presenting cell; studies on priming and expansion of melanA-specific T cells. CIMT 6th Annual Meeting; 2008; Mainz
   Google Scholar
• Grunebach F, Muller MR, Nencioni A, Brossart P. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 2003;10(5):367-74
   PubMed Web of Science ®Google Scholar
• Alexander-Miller MA, Leggatt GR, Sarin A, Berzofsky JA. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 1996;184(2):485-92
   PubMed Web of Science ®Google Scholar
• Curiel-Lewandrowski C, Mahnke K, Labeur M, Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J Immunol 1999;163(1):174-83
   PubMed Web of Science ®Google Scholar
• Tcherepanova IY, Adams MD, Feng X, Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion. BMC Mol Biol 2008;9:90. Published online 17 October 2008, doi:10.1186/1471-2199-9-90
   PubMed Web of Science ®Google Scholar
• Cisco RM, Abdel-Wahab Z, Dannull J, Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4. J Immunol 2004;172(11):7162-8
   PubMed Web of Science ®Google Scholar
• Melero I, Duarte M, Ruiz J, Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther 1999;6(10):1779-84
   PubMed Web of Science ®Google Scholar
• Nishioka Y, Hirao M, Robbins PD, Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999;59(16):4035-41
   PubMed Web of Science ®Google Scholar
• Gonzalez-Carmona MA, Lukacs-Kornek V, CD4 ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Hepatology 2008;48(1):157-68
   PubMed Web of Science ®Google Scholar
• Tomihara K, Kato K, Masuta Y, Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells. Int J Cancer 2007;120(7):1491-8
   PubMed Web of Science ®Google Scholar
• Bonehill A, Van Nuffel AM, Corthals J, Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 2009;15(10):3366-75
   PubMed Web of Science ®Google Scholar
• Willimann K, Legler DF, Loetscher M, The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 1998;28(6):2025-34
   PubMed Web of Science ®Google Scholar
• Cyster JG. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 1999;189(3):447-50
   PubMed Web of Science ®Google Scholar
• Riedl K, Baratelli F, Batra RK, Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol Cancer 2003;2:35. Published online 2 November 2003, doi:10.1186/1476-4598-2-35
   PubMedGoogle Scholar
• Terando A, Roessler B, Mule JJ. Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther 2004;11(3):165-73
   PubMed Web of Science ®Google Scholar
• Xue G, Liu RY, Li Y, Dendritic cells modified with 6Ckine/IFNgamma fusion gene induce specific cytotoxic T lymphocytes in vitro. Cancer Immunol Immunother 2007;56(11):1831-43
   PubMed Web of Science ®Google Scholar
• Arce F, Rowe HM, Chain B, Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization. Mol Ther 2009;17(9):1643-50
   PubMed Web of Science ®Google Scholar
• Wang B, Kuroiwa JM, He LZ, The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. Ann NY Acad Sci 2009;1174:6-17
   PubMed Web of Science ®Google Scholar
• Khan S, Bijker MS, Weterings JJ, Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem 2007;282(29):21145-59
   PubMed Web of Science ®Google Scholar
• Portoukalian J, Carrel S, Dore JF, Rumke P. Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides. EORTC Cooperative Melanoma Group. Int J Cancer 1991;49(6):893-9
   PubMed Web of Science ®Google Scholar
• Sabbatini PJ, Ragupathi G, Hood C, Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 2007;13(14):4170-7
   PubMed Web of Science ®Google Scholar
• Adema GJ, de Vries IJ, Punt CJ, Figdor CG. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol 2005;17(2):170-4
   PubMed Web of Science ®Google Scholar
• West E, Morgan R, Scott K, Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery. J Immunother 2009;32(1):66-78
   PubMed Web of Science ®Google Scholar
• Morse MA, Coleman RE, Akabani G, Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999;59(1):56-8
   PubMed Web of Science ®Google Scholar
• De Vries IJ, Krooshoop DJ, Scharenborg NM, Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003;63(1):12-7
   PubMed Web of Science ®Google Scholar
• de Vries IJ, Lesterhuis WJ, Barentsz JO, Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005;23(11):1407-13
   PubMed Web of Science ®Google Scholar
• Mackensen A, Krause T, Blum U, Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother 1999;48(2-3):118-22
   PubMed Web of Science ®Google Scholar
• Verdijk P, Aarntzen EH, Lesterhuis WJ, Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 2009;15(7):2531-40
   PubMed Web of Science ®Google Scholar
• Fong L, Brockstedt D, Benike C, Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001;166(6):4254-9
   PubMed Web of Science ®Google Scholar
• Dudda JC, Simon JC, Martin S. Dendritic cell immunization route determines CD8+ T cell trafficking to inflamed skin: role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets. J Immunol 2004;172(2):857-63
   PubMed Web of Science ®Google Scholar
• Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity 2002;16(1):1-4
   PubMed Web of Science ®Google Scholar
• Mullins DW, Sheasley SL, Ream RM, Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003;198(7):1023-34
   PubMed Web of Science ®Google Scholar
• Grover A, Kim GJ, Lizee G, Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 2006;12(19):5801-8
   PubMed Web of Science ®Google Scholar
• Harlin H, Meng Y, Peterson AC, Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009;69(7):3077-85
   PubMed Web of Science ®Google Scholar
• Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res 2007;67(2):429-32
   PubMed Web of Science ®Google Scholar
• Errington F, White CL, Twigger KR, Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther 2008;15(18):1257-70
   PubMed Web of Science ®Google Scholar
• Gauvrit A, Brandler S, Sapede-Peroz C, Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res 2008;68(12):4882-92
   PubMed Web of Science ®Google Scholar
• Benencia F, Courreges MC, Fraser NW, Coukos G. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol Ther 2008;7(8):1194-205
   PubMed Web of Science ®Google Scholar
• Errington F, Steele L, Prestwich R, Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008;180(9):6018-26
   PubMed Web of Science ®Google Scholar
• Farrell CJ, Zaupa C, Barnard Z, Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res 2008;14(23):7711-6
   PubMed Web of Science ®Google Scholar
• Power AT, Wang J, Falls TJ, Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 2007;15(1):123-30
   PubMed Web of Science ®Google Scholar
• Iankov ID, Blechacz B, Liu C, Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 2007;15(1):114-22
   PubMed Web of Science ®Google Scholar
• Qiao J, Wang H, Kottke T, Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther 2008;15(8):604-16
   PubMed Web of Science ®Google Scholar
• Qiao J, Kottke T, Willmon C, Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 2008;14(1):37-44
   PubMed Web of Science ®Google Scholar
• Ilett EJ, Prestwich RJ, Kottke T, Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther 2009;16(5):689-99
   PubMed Web of Science ®Google Scholar
• Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5(4):296-306
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5(10):987-95
   PubMed Web of Science ®Google Scholar
• Diaz RM, Galivo F, Kottke T, Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 2007;67(6):2840-8
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27(34):5763-71
   PubMed Web of Science ®Google Scholar
• van Baren N, Bonnet MC, Dreno B, Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005;23(35):9008-21
   PubMed Web of Science ®Google Scholar
• Amato RJ, Drury N, Naylor S, Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a Phase 2 trial. J Immunother 2008;31(6):577-85
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Cohen S, Cheung K, Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther 2006;17(2):239-44
   PubMed Web of Science ®Google Scholar
• Kottke T, Thompson J, Diaz RM, Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res 2009;15(2):561-9
   PubMed Web of Science ®Google Scholar